Aponermin for injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Wuhan Hiteck Biopharmaceutical Co., Ltd.
Medicine type: Biologic
Therapeutic area: Oncology
Indications recorded in the public source: With thalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least two previous systemic treatment regimens. Patients refractory to a previous regimen containing an immunomodulatory agent, such as lenalidomide or thalidomide, should not receive this combination.
Indication source and scope: Source date(s): 2024, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: Indications checked against an official public submission. The full original prescribing information is still unavailable.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Restricted to adults with relapsed or refractory multiple myeloma after at least two previous systemic treatment regimens. Patients refractory to a previous immunomodulatory-agent-containing regimen should not receive this combination.
Insurance period: 2025-01-01 to 2026-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions